{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-397221","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2026-09-22T11:08:41+00:00","discovered_at":"2026-09-22T11:10:00.273228+00:00","generated_at":"2026-09-22T11:10:28.548670+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lexeo to acquire Mantle for up to $21.3M; adds FA pipeline and collaborations","bullets":["Acquisition: $8.3M upfront (cash+equity) plus up to $13M milestones for Mantle; total potential $21.3M; close expected Q3 2026.","Mantle pipeline adds LX3010 (oral, ~6-pt mFARS improvement, 9x frataxin increase), LX3030, LX3050, LX3070 for FA.","Collaborations: Weill Cornell (cerebellar sequential dosing), Vivet (VTX-PID option), Apertura (CapX capsid option) to support LX2006.","LX2006 SUNRISE-FA 2 topline on track for 2H 2027; CLARITY-FA has 22 participants enrolled/imminently enrolling.","Cash runway into 2028 unchanged; expects to advance one acquired program to clinic and submit an IND in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-397221","json":"https://secwatch.observer/filing/0001193125-26-397221.json","markdown":"https://secwatch.observer/filing/0001193125-26-397221.md","text":"https://secwatch.observer/filing/0001193125-26-397221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/0001193125-26-397221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/lxeo-20260916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-22T11:10:28.548670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}